Kaleido Biosciences

50 articles with Kaleido Biosciences

• Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

  1/14/2021

  Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021

• Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Kaleido Biosciences, Inc., announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. EST on Thursday, Jan. 14, 2021.

• Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19Topline data for two studies of KB109 are expected in the first quarter of 2021

  1/4/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to-moderate COVID-19.

• Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Kaleido Biosciences, Inc., announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020.

• Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/2/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quarter 2020 and provided a corporate update. “Kaleido continues to build momentum with the development of interventions based on our Microbiome Metabolic Therapy, or MMT™, platform and evaluate the highly diverse applications of

• Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences

  10/7/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that data from its Microbiome Metabolic Therapy (MMT™) programs for hepatic encephalopathy, cardiovascular and liver disease, and COVID-19 disease have been accepted for poster presentations at upcoming scientific conferences.

• Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline

  10/6/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021. Previous projections had indic

• Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer

  10/1/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed President and Chief Executive Officer and a member of the company’s Board of Directors, effective October 13, 2020. Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but

• Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative ColitisTop-line safety, tolerability and activity results expected in mid-2021

  9/29/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT™) candidate KB295 in patients with mild-to-moderate ulcerative colitis (UC).

• Kaleido Biosciences to Present at Upcoming September 2020 Investor Conferences

  9/9/2020

  Kaleido Biosciences, Inc., announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferences in September.

• Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress™ (EASL)

  8/27/2020

  Kaleido Biosciences, Inc. announced that data from Microbiome Metabolic Therapy candidate KB174 for hepatic encephalopathy will be featured during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.

• Kaleido Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference

  8/5/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, will participate in a fireside chat at the virtual Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 3:30 p.m. ET. A live webcast will be available in the Investors & Media

• Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/4/2020

  - COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 -   LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced financial results for the second quarter 2020 and provided a

• Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19

  7/23/2020

  - Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -

• Kaleido Biosciences Announces CEO Leadership Transition

  6/16/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton has chosen to step down from her position as President and Chief Executive Officer in order to return to the United Kingdom and attend to an unexpected family health matter.

• Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

  6/8/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that in light of the COVID-19 pandemic, its 2020 Annual Meeting of Stockholders will now be held solely by live webcast to comply with public health recommendations and protect the health of employees, Stockholders and directors. Stockholders will

• Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference

  6/4/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will participate in a fireside chat during the virtual Goldman Sachs 41 st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 11:20 a.m. ET. A live webcast will be availab

• Kaleido Biosciences Announces Proposed Public Offering of Common Stock - Jun 01, 2020

  6/1/2020

  Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that it intends to sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering.

• Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

  6/1/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $7.50 per share.

• Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results

  5/14/2020

  Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020